Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort

Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels

(2014) Michael Droste et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Factors influencing the outcome of microsurgical transsphenoidal surgery for pituitary adenomas: A study on 184 patients

(2014) Kostas Lampropoulos et al.   Hormones-International Journal of Endocrinology and Metabolism

Somatostatin receptors: From signaling to clinical practice

(2013) Marily Theodoropoulou et al.   FRONTIERS IN NEUROENDOCRINOLOGY

Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register

(2012) Christof Schöfl et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY

(2012) A. J. van der Lely et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly

(2012) Federico Gatto et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pegvisomant and cabergoline combination therapy in acromegaly

(2012) I. Bernabeu et al.   Pituitary

Self-perceived quality of life predicts mortality risk better than a multi-biomarker panel, but the combination of both does best

(2011) Robin Haring et al.   BMC Medical Research Methodology

Endoscopic Transsphenoidal Surgery for Acromegaly: Remission Using Modern Criteria, Complications, and Predictors of Outcome

(2011) John A. Jane et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Models to predict changes in serum IGF1 and body composition in response to GH replacement therapy in GH-deficient adults

(2010) Edna J L Barbosa et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Influence of pegvisomant on serum ghrelin and leptin levels in acromegalic patients

(2010) J Roemmler et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

A Consensus on Criteria for Cure of Acromegaly

(2010) A. Giustina et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Age and sex as predictors of biochemical activity in acromegaly: analysis of 1485 patients from the German Acromegaly Register

(2009) S. Petersenn et al.   CLINICAL ENDOCRINOLOGY

Sex-related psychological effects on metabolic control in type 2 diabetes mellitus

(2009) G. Kacerovsky-Bielesz et al.   DIABETOLOGIA

Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study

(2009) M Buchfelder et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY

(2009) Thierry Brue et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

The German ACROSTUDY: past and present

(2009) M Buchfelder et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008

(2009) Ali Montazeri   Health and Quality of Life Outcomes

Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly

(2009) Marily Theodoropoulou et al.   INTERNATIONAL JOURNAL OF CANCER

The Exon 3-Deleted Growth Hormone Receptor Is Associated with Better Response to Pegvisomant Therapy in Acromegaly

(2009) Ignacio Bernabeu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Are health-related quality-of-life and self-rated health associated with mortality? Insights from Translating Research Into Action for Diabetes (TRIAD)

(2009) Laura N. McEwen et al.   Primary Care Diabetes